In the present study, after treatment, the levels of serum HE4, CA125, and CA199 in the observation group were lower than those in the control group, indicating that olaparib combined with bevacizumab could more effectively reduce the serum tumor marker levels in patients with platinum-resistant recurrent ovarian epithelial carcinoma, but the specific mechanism remains to be further explored. This evidence concerns the gene WFDC2 and neoplasm.